nafronyl has been researched along with Muscle Contraction in 7 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
Excerpt | Relevance | Reference |
---|---|---|
"Endothelin-1 (ET-1) causes urinary bladder smooth muscle contraction and the endothelin receptors A and B (ET(A) and ET(B)) are both known to be present in the rabbit urinary bladder." | 3.71 | Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. ( Calvert, RC; Dashwood, MR; Khan, MA; Mikhailidis, DP; Morgan, RJ; Mumtaz, FH; Thompson, CS, 2002) |
" Cumulative dose-response curves were derived with and without NFT at 10(-9) and 10(-6) mol/l concentrations." | 1.29 | Microvascular disease and anastomotic dehiscence in the colon. ( Dawson, PM; Fawcett, A; Nott, DM; O'Malley, MK; Shankar, A; Springall, RG; Vashisht, R, 1995) |
" Cumulative dose-response curves and maximal contraction in response to serotonin were recorded and this was repeated in the presence of NFT at 10(-6) and 10(-3) mol/l." | 1.28 | Serotonin-induced contractility in human saphenous vein is inhibited by naftidrofuryl. ( Leathard, HL; O'Malley, MK; Sharp, EJ; Sian, M; Vashisht, R, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 5 (71.43) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Calvert, RC | 1 |
Mumtaz, FH | 1 |
Dashwood, MR | 1 |
Khan, MA | 1 |
Morgan, RJ | 1 |
Mikhailidis, DP | 1 |
Thompson, CS | 1 |
Kienbaum, P | 1 |
Braun, M | 1 |
Hohlfeld, T | 1 |
Weber, AA | 1 |
Sarbia, M | 1 |
Schrör, K | 2 |
Pécot-Dechavassine, M | 1 |
Mira, JC | 1 |
Verheggen, R | 1 |
Fawcett, A | 1 |
Vashisht, R | 2 |
Shankar, A | 1 |
Dawson, PM | 1 |
O'Malley, MK | 2 |
Nott, DM | 1 |
Springall, RG | 1 |
Sian, M | 1 |
Sharp, EJ | 1 |
Leathard, HL | 1 |
Ducarne, H | 1 |
1 trial available for nafronyl and Muscle Contraction
Article | Year |
---|---|
Evaluation of a vasoactive substance, naftidrofuryl, during the rehabilitation phase after an ischaemic insult.
Topics: Activities of Daily Living; Aged; Double-Blind Method; Female; Furans; Humans; Intracranial Embolism | 1986 |
6 other studies available for nafronyl and Muscle Contraction
Article | Year |
---|---|
Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl.
Topics: Animals; Autoradiography; Binding Sites; Depression, Chemical; Dose-Response Relationship, Drug; End | 2002 |
Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function.
Topics: Acetylcholine; Administration, Oral; Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; C | 1995 |
Electrophysiological evaluation of the effects of naftidrofuryl on skeletal muscle reinnervation in the rat.
Topics: Animals; Axons; Electromyography; Evoked Potentials; Male; Motor Endplate; Motor Neurons; Muscle Con | 1994 |
Effect of naftidrofuryl on platelet-induced vasospasm in vitro. Role of antiserotonergic actions.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Animals; | 1993 |
Microvascular disease and anastomotic dehiscence in the colon.
Topics: Anastomosis, Surgical; Colon; Dose-Response Relationship, Drug; Humans; Mesenteric Artery, Inferior; | 1995 |
Serotonin-induced contractility in human saphenous vein is inhibited by naftidrofuryl.
Topics: Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Muscle Contraction; Muscle, Smooth, | 1992 |